The value of SDC2 and Septin9 combined with serum tumor markers in early diagnosis of colorectal cancer

Q: What is the study’s primary objective?

To assess how well combined detection of Septin9 and SDC2 methylation markers, together with serum tumor markers, supports early diagnosis of colorectal cancer.

Q: How were the patient groups defined and what indicators were measured?

The study included 116 colorectal cancer patients, 31 adenoma patients, and 44 controls. Septin9, SDC2, fecal occult blood (FOB), and serum tumor markers (CEA, CA199, CA125, CA724) were measured, and diagnostic performance was evaluated using ROC curves.

Q: What diagnostic performance did the combined Septin9 and SDC2 detection show for early-stage disease?

For stage I–III colorectal cancer, the combined Septin9+SDC2 positivity rates were 81.3%, 78.9%, and 90.2%, exceeding those of the combined four serum tumor markers. The combined two-gene detection also demonstrated higher sensitivity and AUC than FOB and the four-marker combination.

Sep 21, 2026

Upload by Miles

Objective: evaluate the diagnostic significance of combined detection using Septin9 and syndecan-2 (SDC2) methylation markers together with serum tumor markers for early colorectal cancer diagnosis. Methods: 116 colorectal cancer patients (Dec 2022–Feb 2024), 31 adenoma patients, and 44 controls were analyzed. Septin9, SDC2, fecal occult blood (FOB), and serum markers (CEA, CA199, CA125, CA724) were measured; ROC curves assessed single and combined indicator performance. Results: the cancer group showed higher positivity and ROC performance for the Septin9+SDC2 and all-seven combinations. Conclusion: SDC2 has high sensitivity and, combined with Septin9, improves diagnostic accuracy for early-stage colorectal cancer.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages10

Reading Time25 min

AccessFree to download

Abstract

Objective

Methods

Results

Conclusion

Introduction

International Journal of Colorectal Disease (2024) 39:142 [https://doi.org/10.1007/s00384-024-04713-9](https://doi.org/10.1007/s00384-024-04713-9) The value ofSDC2 and Septin9 combined with serum tumor markers in early diagnosis of colorectal cancer Chao‑Shi Zou1 · Yu‑Ling Xie2 · Dong‑Xu Wang3 · Yan‑Ping Liu1 · Ming‑Qiang Li1 · Yi Chen4 · Zhi‑Le Su1 · Kang‑hai Liu1 Accepted: 2 September 2024 / Published online: 17 September 2024 © The Author(s) 2024 Abstract Objective The aim of this study is to evaluate the significance of combined detection of Septin9 and syndecan-2 (SDC2) methylation markers and serum tumor markers for the early diagnosis of colorectal cancer. Methods A total of 116 patients diagnosed with colorectal cancer between December 2022 and February 2024 were designated as the colorectal cancer group. Additionally, 31 patients with colorectal adenoma were assigned to the adenoma group, while 44 individuals undergoing routine physical examinations were included in the control group. Concentrations of Septin9, SDC2, fecal occult blood (FOB), and four tumor markers—carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), carbohydrate antigen 125 (CA125), and carbohydrate antigen 724 (CA724)—were measured. Diagnostic performance was assessed using receiver operating characteristic (ROC) curves for Septin9, SDC2, the four tumor markers, FOB, the combination of Septin9 and SDC2, and the combined use of all seven indicators (CEA, CA19-9, CA125, CA72-4, FOB, Septin9, and SDC2) . Results The colorectal cancer group exhibited the highest positive rates for Septin9, SDC2, the four tumor markers, the combined detection of Septin9 and SDC2, and the combined detection of all seven indicators, compared to both the adenoma and control groups (P < 0.05). The adenoma group also showed higher positive rates than the control group (P < 0.05) . For patients with stage I–III colorectal cancer, the positive rates for the combined detection of Septin9 and SDC2 were 81.3%, 78.9%, and 90.2%, respectively, surpassing those for the combined detection of the four tumor markers (43.8%, 55.3%, and 61.0%). Additionally, the positive rates for the two-gene combination in stage III colorectal cancer were higher than those for FOB (P < 0.05). The sensitivity and area under the curve (AUC) for SDC2 were 73.3% and 0.855, respectively, exceeding the sensitivity and AUC for the combined four tumor markers, which were 60.3% and 0.734 (P < 0.05) . The combined detection of the two methylated genes demonstrated a sensitivity of 86.2% and an AUC of 0.908, outperforming both FOB and the combined detection of the four tumor markers (P < 0 .05) . Conclusion The detection of SDC2 exhibits high sensitivity for colorectal cancer, and when combined with Septin9, it significantly enhances the diagnostic accuracy for early-stage colorectal cancer, offering substantial clinical value. Keywords Colorectal cancer · Methylation · SDC2 · Septin9 Chao-Shi Zou and Yu-Ling Xie contributed equally to this study. * Dong-Xu Wang [dongxuwang_wdx@126.com](dongxuwang_wdx@126.com) 1 Department of Laboratory, The First People’s Hospital of Yulin, 495 Middle Education Road, Yulin 537000, Guangxi Zhuang Autonomous Region, China 2 Department of Laboratory, Yulin Women and Children Health Care Hospital, 290 Qing Ning Road, Yulin 537000, Guangxi Zhuang Autonomous Region, China 3 Department of Endoscopy Center, The First People’s Hospital of Yulin, 495 Middle Education Road, Yulin 537000, Guangxi Zhuang Autonomous Region, China 4 Department of Infection Management, The First People’s Hospital of Yulin, 495 Middle Education Road, Yulin 537000, Guangxi Zhuang Autonomous Region, China Introduction Colorectal cancer continues to present a significant global health challenge as a malignant disease of the digestive tract. Its development typically follows a prolonged course, beginning with normal epithelium, progressing through stages of polyp for

FAQs

What is the study’s primary objective?

To assess how well combined detection of Septin9 and SDC2 methylation markers, together with serum tumor markers, supports early diagnosis of colorectal cancer.

How were the patient groups defined and what indicators were measured?

The study included 116 colorectal cancer patients, 31 adenoma patients, and 44 controls. Septin9, SDC2, fecal occult blood (FOB), and serum tumor markers (CEA, CA199, CA125, CA724) were measured, and diagnostic performance was evaluated using ROC curves.

What diagnostic performance did the combined Septin9 and SDC2 detection show for early-stage disease?

For stage I–III colorectal cancer, the combined Septin9+SDC2 positivity rates were 81.3%, 78.9%, and 90.2%, exceeding those of the combined four serum tumor markers. The combined two-gene detection also demonstrated higher sensitivity and AUC than FOB and the four-marker combination.

Sep 21, 2026

Upload by Miles